hrcak mascot   Srce   HID

Pregledni rad

Cardiovascular effects of oral medications in the treatment of type 2 diabetes

Saša Magaš ; Bjelovar General Hospital, Bjelovar, Croatia

Puni tekst: engleski, pdf (84 KB) str. 345-351 preuzimanja: 126* citiraj
APA 6th Edition
Magaš, S. (2013). Cardiovascular effects of oral medications in the treatment of type 2 diabetes. Cardiologia Croatica, 8 (10-11), 345-351. Preuzeto s https://hrcak.srce.hr/112562
MLA 8th Edition
Magaš, Saša. "Cardiovascular effects of oral medications in the treatment of type 2 diabetes." Cardiologia Croatica, vol. 8, br. 10-11, 2013, str. 345-351. https://hrcak.srce.hr/112562. Citirano 28.11.2020.
Chicago 17th Edition
Magaš, Saša. "Cardiovascular effects of oral medications in the treatment of type 2 diabetes." Cardiologia Croatica 8, br. 10-11 (2013): 345-351. https://hrcak.srce.hr/112562
Harvard
Magaš, S. (2013). 'Cardiovascular effects of oral medications in the treatment of type 2 diabetes', Cardiologia Croatica, 8(10-11), str. 345-351. Preuzeto s: https://hrcak.srce.hr/112562 (Datum pristupa: 28.11.2020.)
Vancouver
Magaš S. Cardiovascular effects of oral medications in the treatment of type 2 diabetes. Cardiologia Croatica [Internet]. 2013 [pristupljeno 28.11.2020.];8(10-11):345-351. Dostupno na: https://hrcak.srce.hr/112562
IEEE
S. Magaš, "Cardiovascular effects of oral medications in the treatment of type 2 diabetes", Cardiologia Croatica, vol.8, br. 10-11, str. 345-351, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/112562. [Citirano: 28.11.2020.]
Puni tekst: hrvatski, pdf (84 KB) str. 345-351 preuzimanja: 293* citiraj
APA 6th Edition
Magaš, S. (2013). Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2. Cardiologia Croatica, 8 (10-11), 345-351. Preuzeto s https://hrcak.srce.hr/112562
MLA 8th Edition
Magaš, Saša. "Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2." Cardiologia Croatica, vol. 8, br. 10-11, 2013, str. 345-351. https://hrcak.srce.hr/112562. Citirano 28.11.2020.
Chicago 17th Edition
Magaš, Saša. "Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2." Cardiologia Croatica 8, br. 10-11 (2013): 345-351. https://hrcak.srce.hr/112562
Harvard
Magaš, S. (2013). 'Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2', Cardiologia Croatica, 8(10-11), str. 345-351. Preuzeto s: https://hrcak.srce.hr/112562 (Datum pristupa: 28.11.2020.)
Vancouver
Magaš S. Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2. Cardiologia Croatica [Internet]. 2013 [pristupljeno 28.11.2020.];8(10-11):345-351. Dostupno na: https://hrcak.srce.hr/112562
IEEE
S. Magaš, "Kardiovaskularni učinci oralnih lijekova za liječenje šećerne bolesti tipa 2", Cardiologia Croatica, vol.8, br. 10-11, str. 345-351, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/112562. [Citirano: 28.11.2020.]

Sažetak
Diabetes mellitus (DM) is in rise worldwide. More than 90% of patients suffer from type 2 DM. The majority of patients suffering from type 2 DM are treated with oral medications. In addition to lowering glycemia, the medications for treatment of DM may either have direct effects on the cardiovascular system or the effects on cardiovascular risk factors. The administration of sulfonylurea and thiazolidinedione attracts the most attention because of the potential negative impact on the in- creased risk of death or heart failure. On the other hand, better pleiotropic and metabolic effects of pioglitazone and metformin are known. Repaglinide administered with metformin may increase the cardiovascular risk, although it has a positive effect on lowering inflammatory cytokines. Dipeptidyl peptidase-4 inhibitors do not increase cardiovascular risks, and they improve metabolic variables.

Ključne riječi
oral hypoglycemics; cardiovascular risks; sulfonylurea; metformin; thiazolidinediones

Hrčak ID: 112562

URI
https://hrcak.srce.hr/112562

[hrvatski]

Posjeta: 645 *